Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies
Conclusions We suggest that FGFR2 inhibition has potent effects on ovarian cancer growth in preclinical studies.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Epithelial Cancer | Investigational New Drugs | Men | Ovarian Cancer | Ovaries | Study